1Q09 Earnings Release
Tuesday, May, 5th, 2009.
Highlights For The Period




 • For the third quarter in a row, a generation of positive operating cash flow reaching R$ ...
Gross Revenues Evolution



                                              In R$ MM




                              714.9...
Gross Revenues Breakdown




          (R$ Million)           1Q09    1Q08    Chg %    4Q08    Chg %
           Branded   ...
Market Share (%)




                                           11.7   11.8
                                    11.5
     ...
Gross Profit and Revenues
from Services to Suppliers



                                                                  ...
Operating Expenses



                                                                                                    ...
Net Financial Expenses



                                                    In R$ MM
                                   ...
Net Income



                                           In R$ MM
                                     and as % Net Revenu...
Adjusted EBITDA and EBITDA Margin



                                                            In R$ MM
                ...
Cash Flow




                                                       CASH FLOW
(R$ Million)                               ...
Cash Cycle




                                                3Q06   4Q06   1Q07   2Q07   3Q07   4Q07   1Q08   2Q08   3Q0...
Indebtedness




                                   Net Debt (R$ MM) and Net Debt / Ebitda
          In R$ MM
            ...
Capex



                                    In R$ MM
                              and as % Net Revenues




            ...
Operating Indicators




              Service Level                        Logistics E.P.M
     (units served / units req...
Share Performance




 185   * 100 pts basis on 25/oct/2006

 175

 165

 155

 145

 135

 125

 115

 105

  95

  85

 ...
Analyst Coverage




              Company          Analyst


                               Alexandre Falcão - Flávio Que...
IR Contacts

               Max Fischer
         CFO and IR Director

                Beatriz Diez
             IR Coorden...
Upcoming SlideShare
Loading in …5
×

Earnings Release 1Q09 Presentation

226
-1

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
226
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Earnings Release 1Q09 Presentation

  1. 1. 1Q09 Earnings Release Tuesday, May, 5th, 2009.
  2. 2. Highlights For The Period • For the third quarter in a row, a generation of positive operating cash flow reaching R$ 36.6 million in this quarter, 6.5% of the net operating revenue. • Net debt dropped in 19.2%, R$ 28.7 million, in relation to the previous quarter, reducing the Company’s net debt / Ebitda ratio to 1.6x, coming from 1.9x (december 2008). • For the fifth quarter in a row we show a reduction of the accounts receivables terms, in 3.5 days, reaching 42.4 days, the lowest level since the year of 2006. • For the second quarter in a row an adjusted gross margin recovery (added to revenues from services to suppliers) reaching 11.2% in the 1Q09, 0,2 percentage point above the gross margin of the 4Q08, and also of the 1Q08. • The annual price increase which occurred on March, 31st, 2009 was of 5.9%, 90% above the one registered in the previous year. • The ebitda was of R$ 17.1 million, maintaining the ebitda margin in line with the same period of the previous year in 3.0% of the net operating revenue. • Profarma announced to the market on April, 3rd, 2009, an additive to the company’s share repurchase program, increasing the maximum quantity of the shares to be acquired from 1.062.500 common shares to 1.700.000 shares. 2
  3. 3. Gross Revenues Evolution In R$ MM 714.9 700.9 661.8 1Q08 4Q08 1Q09 3
  4. 4. Gross Revenues Breakdown (R$ Million) 1Q09 1Q08 Chg % 4Q08 Chg % Branded 453.9 501.8 -9.6% 489.9 -7.4% Generics 29.5 33.9 -12.9% 41.5 -28.8% OTC 129.3 119.2 8.5% 127.6 1.4% Health and Beauty 23.2 30.9 -25.0% 31.4 -26.3% Hospitals + Vaccines 25.8 15.1 71.0% 24.4 5.8% Total 661.8 700.9 -5.6% 714.9 -7.4% 4
  5. 5. Market Share (%) 11.7 11.8 11.5 10.9 9.9 9.6 9.6 9.3 2004 2005 2006 2007 2008 1Q08 4Q08 1Q09 Source: IMS 5
  6. 6. Gross Profit and Revenues from Services to Suppliers In R$ MM and as % Net Revenues 11.2% 11.0% 11.0% 7.4 16.5 5.3 59.7 57.8 51.0 1Q08 4Q08 1Q09 Gross Profit Revenues from Services to Suppliers Adjusted GP Margin (%) 6
  7. 7. Operating Expenses In R$ MM and as % Net Revenues 8.2% 7.8% 7.9% 47.7 48.1 45.9 1Q08 4Q08 1Q09 EXPENSES: General and Administrative + Selling and Marketing + Logistics and Distribution 7
  8. 8. Net Financial Expenses In R$ MM and as % Net Revenues 1.6% 1.4% 0.8% 10.0 7.8 5.0 1Q08 4Q08 1Q09 8
  9. 9. Net Income In R$ MM and as % Net Revenues 1.5% 1.2% 1.1% 9.4 6.5 6.7 1Q08 4Q08 1Q09 9
  10. 10. Adjusted EBITDA and EBITDA Margin In R$ MM and as % Net Revenues 3.5% 3.0% 3.0% 21.4 18.1 17.1 1Q08 4Q08 1Q09 10
  11. 11. Cash Flow CASH FLOW (R$ Million) 1Q09 1Q08 Chg. % 4Q08 Chg. % Cash Flow Generated / (Used) in Operating Activities 36.6 5.7 542.1% 10.6 245.3% Internal Cash Generation 11.4 14.8 -22.7% 10.7 6.2% Operating Assets Variation 25.2 (9.1) - (0.1) - Trade Accounts Receivable 51.5 29.9 72.4% 43.8 17.6% Inventories 8.3 19.3 -56.9% (18.7) - Suppliers (25.3) (49.4) 48.9% (6.9) -267.5% Other Items (9.4) (8.8) -6.7% (18.4) 48.9% Cash Flow (Used) in Investing Activities (3.3) (2.1) -57.1% (4.2) 21.4% Cash Flow Generated / (Used) by Financing Activities (6.2) (34.4) 82.0% (15.3) 59.5% Net Increase / (Decrease) in Cash 27.1 (30.8) - (8.8) - 11
  12. 12. Cash Cycle 3Q06 4Q06 1Q07 2Q07 3Q07 4Q07 1Q08 2Q08 3Q08 4Q08 1Q09 Cash Cycle - Days * 49.3 53.4 62.5 69.6 67.8 64.3 68.8 67.2 61.8 65.8 67.9 Accounts Receivable (1) 45.2 50.0 54.6 53.1 50.9 51.7 50.7 49.2 47.0 45.9 42.4 Inventories (2) 33.1 44.7 43.4 47.2 41.3 48.6 47.9 45.7 42.5 49.9 54.0 Accounts Payable (3) 29.0 41.3 35.6 30.7 24.5 36.0 29.8 27.7 27.7 29.9 28.5 *Average (1) Average of Gross Revenues in the Quarter (2) Average of COGS in the Quarter (3) Average of COGS in the Quarter 12
  13. 13. Indebtedness Net Debt (R$ MM) and Net Debt / Ebitda In R$ MM 1.9 1.6 1.5 149.4 124.8 120.7 1Q08 4Q08 1Q09 * Ebitda = Accumulated last 12 months 13
  14. 14. Capex In R$ MM and as % Net Revenues 0.7% 0.6% 0.3% 4.2 3.3 2.1 1Q08 4Q08 1Q09 14
  15. 15. Operating Indicators Service Level Logistics E.P.M (units served / units requested) (Errors per Million) 100.0 91.2% 95.0 83.0 90.7% 90.2% 1Q08 4Q08 1Q09 1Q08 4Q08 1Q09 15
  16. 16. Share Performance 185 * 100 pts basis on 25/oct/2006 175 165 155 145 135 125 115 105 95 85 75 65 55 45 35 25 15 Ibovespa Profarma 16
  17. 17. Analyst Coverage Company Analyst Alexandre Falcão - Flávio Queiroz Telephone: (55 11) 3048-6270 / (55 11) 3048-6196 Morgan Stanley E-mail: alexandre.falcao@morganstanley.com E-mail: flavio.queiroz@morganstanley.com João Carlos dos Santos - Alexandre Pizano Telephone: (55 11) 2188-4316 / (55 11) 2188-4024 Merril Lynch E-mail: joaocarlos_santos@ml.com E-mail: alexrande_pizano@ml.com Marcel Moraes - Thais Pinho Telephone: (55 11) 3841-6302 / (55 11) 3841-6341 Credit Suisse E-mail: marcel.moraes@credit-suisse.com E-mail: thais.pinho@credit-suisse.com Renata Faber - Marcio Osako Telephone: (55 11) 3073-3017 / (55 11) 3073-3040 Itaú BBA E-mail: renata.faber@itau.com.br E-mail: marcio.osako@itau.com.br 17
  18. 18. IR Contacts Max Fischer CFO and IR Director Beatriz Diez IR Coordenador Telephone.: 55 (21) 4009 0276 E-mail: ri@profarma.com.br www.profarma.com.br/ir
  1. A particular slide catching your eye?

    Clipping is a handy way to collect important slides you want to go back to later.

×